bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a research note published on Tuesday. The firm issued a sell rating on the biotechnology company’s stock.

BLUE has been the subject of a number of other reports. JPMorgan Chase & Co. upgraded shares of bluebird bio from an “underweight” rating to a “neutral” rating in a research report on Monday, February 24th. Barclays upped their target price on shares of bluebird bio from $2.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, December 31st. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $80.00 target price on shares of bluebird bio in a report on Friday, November 15th. Bank of America lowered shares of bluebird bio from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $60.00 to $10.00 in a report on Friday, November 15th. Finally, Baird R W lowered shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $44.14.

bluebird bio Stock Performance

NASDAQ:BLUE opened at $3.82 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51. The company has a fifty day moving average of $7.19 and a two-hundred day moving average of $8.78. The stock has a market capitalization of $37.14 million, a PE ratio of -0.10 and a beta of 0.68. bluebird bio has a fifty-two week low of $3.56 and a fifty-two week high of $33.20.

Institutional Investors Weigh In On bluebird bio

A number of hedge funds have recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in shares of bluebird bio by 3.7% in the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after purchasing an additional 166,771 shares during the period. State Street Corp grew its holdings in shares of bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after purchasing an additional 43,382 shares during the period. FMR LLC grew its holdings in shares of bluebird bio by 8.1% in the third quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock valued at $1,289,000 after purchasing an additional 186,903 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of bluebird bio by 2,270.2% in the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 355,562 shares during the period. Finally, Barclays PLC grew its holdings in shares of bluebird bio by 273.7% in the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 184,605 shares during the period. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.